Carlos Bachier
Hematology · San Juan, PRNPI 1588621031
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (32.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Sanofi at 34.5% of the total. Reporting peaked in 2019 at $11,358 and has fallen 80.5% since, to $2,215 in 2025.
Across 197 payments — averaging $160.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$11K
- Kadmon Pharmaceuticals LLC$9K
- E.r. Squibb & Sons, L.L.C.$7K
- Gilead$561
- Johnson & Johnson$454
- AbbVie$453
- plus $4K from 29 others
Across 208 payments — averaging $6647.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$708K
- CSL Behring$281K
- Incyte Corporation$159K
- Janssen Research & Development, LLC$89K
- Kadmon Corporation LLC$39K
- Pfizer$31K
- plus $75K from 7 others
What the payments were for
- Consulting fees$10,27332%
- Speaking & faculty fees$9,80931%
- Travel & lodging$1,2914%
- Food & beverage$5,74018%
- Education$4,56814%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 10 | $10,931 |
| Kadmon Pharmaceuticals LLC | 5 | $8,636 |
| E.r. Squibb & Sons, L.L.C. | 13 | $6,652 |
| Gilead(2 entities) | 8 | $561 |
| Johnson & Johnson | 21 | $454 |
| AbbVie | 20 | $453 |
| Sanofi-aventis U.S. LLC | 9 | $410 |
| Incyte Corporation | 10 | $339 |
| Genentech USA, Inc. | 10 | $336 |
| AstraZeneca(2 entities) | 12 | $320 |
| Astellas Pharma US Inc | 5 | $277 |
| Bristol Myers Squibb | 2 | $260 |
| Tempus AI, Inc | 5 | $232 |
| Genmab U.S., Inc. | 4 | $214 |
| Rigel Pharmaceuticals, Inc. | 5 | $197 |
| Eli Lilly Export S.A. Puerto Rico Branch | 7 | $160 |
| Amgen | 8 | $158 |
| Novartis | 5 | $133 |
| Servier Pharmaceuticals LLC | 1 | $128 |
| Adaptive Biotechnologies Corporation | 5 | $116 |
| Sobi, Inc | 5 | $114 |
| Beigene USA, Inc. | 5 | $111 |
| Syndax Pharmaceuticals, Inc. | 3 | $73 |
| Pfizer | 3 | $63 |
| Jazz Pharmaceuticals Inc. | 3 | $56 |
| Taiho Oncology, Inc. | 2 | $48 |
| Karyopharm Therapeutics Inc. | 2 | $46 |
| Beone Medicines USA, Inc. | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Legend Biotech USA Inc. | 1 | $26 |
| PBG Puerto Rico LLC | 1 | $25 |
| CSL Behring | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Caris MPI, Inc. | 1 | $18 |
| Boston Scientific | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.